Iparomlimab and Tuvonralimab With Chemoradiation for the Treatment of Locally Recurrent and Oligometastatic Cervical Cancer

• Status: RECRUITING
• Trial end date: 2028-12-31

Summary

The goal of this clinical trial is to evaluation the efficacy and safety of iparomlimab and tuvonralimab, paclitaxel + cisplatin/carboplatin combined with radiotherapy of locally recurrent and oligometastatic cervical cancer.The main questions it aims to answer are:

1. Does the combination therapy improve the overall response rate (ORR), progression-free survival (PFS), disease control rate (DCR), overall survival (OS), and safety in participants?

2. What are the predictive biomarkers of treatment efficacy, and how can this information better guide the use of immune-oncology drugs in combination therapy?

Participants will:

• Receive iparomlimab and tuvonralimab, Paclitaxel + Cisplatin/Carboplatin and radiation therapy according to a specified protocol.
• Visit the clinic for regular checkups and tests throughout the treatment period.
• Be monitored for and have records kept of ORR, PFS, DCR, OS, and safety.
• Provide hematologictissue and stool samples to explore biomarkers.

This study will help determine if this combination therapy can become a new standard of care for patients with locally recurrent and oligometastatic cervical cancer as well as identify biomarkers to better guide treatment strategies.

• Phase: PHASE2

Details

• Lead Sponsor: Shandong Cancer Hospital and Institute
• Treatments: Carboplatin; Cisplatin; Paclitaxel; Radiotherapy